Filing Flows › Aspira Women's Health (AWHL) › R&D spending
Aspira Women's Health (AWHL) R&D spending by quarter
Aspira Women's Health's R&D spending was $692K in Q2 2026 (second quarter 2026), -44% from Q1 2026. Over the last 6 quarters it ranged from $462K (Q4 2025) to $1.2M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $692K | -44% | -2% |
| Q1 2026 | $1.2M | +165% | — |
| Q4 2025 | $462K | -37% | -8% |
| Q3 2025 | $739K | +5% | — |
| Q2 2025 | $704K | +41% | — |
| Q4 2024 | $500K | — | — |
Q2 2026 at a glance
Aspira Women's Health, Q2 2026: revenue $2.0M (-15% year over year), operating margin -89.7%, net loss $2.4M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Aspira Women's Health's R&D spending?
Aspira Women's Health's R&D spending was $692K in Q2 2026 (second quarter 2026), -44% from Q1 2026.
How has Aspira Women's Health's R&D spending changed?
Over the last 6 quarters it ranged from $462K (Q4 2025) to $1.2M (Q1 2026).